Ionis Pharmaceuticals, Inc. — Fiscal 2021 Form 10-K Summary
Business context and reporting period
Ionis is a biotechnology company focused on RNA-targeted antisense therapeutics. The filing covers the fiscal year ended December 31, 2021. Ionis operated as a single segment following the full integration of Akcea Therapeutics. It had three marketed medicines—SPINRAZA, TEGSEDI and WAYLIVRA—and six medicines in Phase 3 development for eight indications.
Ionis reported unaudited fourth-quarter results for the three months ended December 31, 2021. The company had 141.2 million common shares outstanding at year-end and 660 employees as of February 16, 2022.
Key financial metrics
| Metric | 2021 | 2020 |
|---|---|---|
| Total revenue | $810.5 million | $729.3 million |
| Commercial revenue | $342.4 million | $364.7 million |
| Research and development revenue | $468.1 million | $364.6 million |
| Total operating expenses | $840.6 million | $901.3 million |
| Loss from operations | $(30.2) million | $(172.1) million |
| Net loss attributable to Ionis common stockholders | $(28.6) million | $(444.3) million |
| Basic and diluted loss per share | $(0.20) | $(3.18) |
| Net cash provided by operating activities | $30.8 million | $35.9 million |
| Cash, cash equivalents and short-term investments | $2.115 billion | $1.892 billion |
Revenue increased 11.1% year over year. The operating margin was approximately negative 3.7%, and the net margin was approximately negative 3.5%. Revenue was highly dependent on collaboration-related payments: R&D revenue represented approximately 58% of total revenue in 2021.
- SPINRAZA royalties declined to $267.8 million from $286.6 million, reflecting competitive and pricing pressure.
- TEGSEDI and WAYLIVRA revenue declined to $55.5 million from $70.0 million, partly because the Sobi distribution arrangements shifted the revenue model from direct product sales to distribution fees.
- Licensing and other royalty revenue increased to $19.1 million from $8.1 million.
- R&D revenue included $200 million from AstraZeneca for the eplontersen license, $60 million from Biogen for ION306, and a $25 million Novartis milestone related to pelacarsen enrollment.
- Research, development and patent expense increased to $643.5 million from $535.1 million, including $34.8 million recognized for the Bicycle technology license.
- Selling, general and administrative expense declined to $186.3 million from $354.3 million because of Akcea integration and commercial restructuring efficiencies.
Fourth-quarter 2021 results
| Metric | Q4 2021 | Q4 2020 |
|---|---|---|
| Revenue | $440.0 million | $290.3 million |
| Operating expenses | $219.4 million | $312.9 million |
| Income (loss) from operations | $220.6 million | $(22.7) million |
| Net income (loss) | $224.6 million | $(355.7) million |
| Diluted earnings (loss) per share | $1.41 | $(2.54) |
The fourth-quarter profit was materially affected by the recognition of license and milestone revenue, including the $200 million eplontersen upfront payment. It should not be interpreted as a recurring quarterly earnings level.
Liquidity, debt and capital resources
- Cash and cash equivalents were $869.2 million, and short-term investments were $1.246 billion at December 31, 2021.
- Ionis generated $30.8 million of operating cash flow and ended the year with $771.7 million of stockholders’ equity and an accumulated deficit of $1.160 billion.
- In April 2021, Ionis issued $632.5 million of 0% convertible senior notes due April 2026. It used proceeds to repurchase $247.9 million principal amount of 1% notes and paid the remaining $62.0 million principal at maturity in November 2021.
- At year-end, carrying values included $619.1 million of 0% notes, $542.3 million of 0.125% notes due December 2024, and $59.7 million of mortgage debt.
- Total contractual obligations were $1.285 billion, including $632.5 million of 0% notes, $550.9 million of 0.125% notes including interest, mortgage obligations and operating leases.
- Management stated that available cash, cash equivalents and short-term investments were sufficient to fund operations in the short and longer term. No off-balance-sheet arrangements were reported.
Material changes versus the prior comparable period
- Revenue rose by $81.2 million, driven primarily by higher partner payments and license fees, while commercial revenue declined by $22.3 million.
- Operating expenses fell by $60.7 million, primarily because 2020 included $89.6 million of Akcea merger and European restructuring expenses. Excluding those items, 2021 operating expenses increased due to pipeline investment.
- Net loss narrowed substantially, mainly because 2020 included a $341 million non-cash tax expense from increasing the valuation allowance on deferred tax assets.
- Cash, cash equivalents and short-term investments increased by $222.6 million, supported by more than $760 million of partner payments and the convertible note issuance.
- Ionis transitioned European TEGSEDI and WAYLIVRA commercialization and North American TEGSEDI commercialization to Sobi, reducing direct commercial infrastructure.
- Phase 3 activity expanded to six medicines and eight indications, including newly initiated Phase 3 programs for olezarsen, donidalorsen and ION363.
Guidance, outlook, commentary and unusual items
Management stated that Ionis exceeded its 2021 financial guidance, achieving $810 million of revenue and maintaining a year-end cash balance of approximately $2.1 billion. The filing does not provide a clear quantitative revenue or earnings guidance range for 2022.
- Eplontersen: the NEURO-TTRansform Phase 3 study was fully enrolled, with data expected in mid-2022; AstraZeneca received exclusive commercialization rights outside the U.S., subject to stated exceptions.
- Olezarsen: Phase 3 studies were underway in familial chylomicronemia syndrome and severe hypertriglyceridemia.
- Donidalorsen: the Phase 3 OASIS-HAE study began after positive Phase 2 results.
- Pelacarsen: Novartis’ Phase 3 cardiovascular outcomes study reached 50% enrollment.
- Tofersen: the Phase 3 VALOR study did not meet its primary endpoint, although favorable trends appeared in several secondary and exploratory measures. Biogen was engaging with regulators regarding next steps.
- Tominersen: Roche stopped dosing in the Phase 3 GENERATION HD1 study in 2021 following a benefit-risk review; in January 2022, Roche announced plans for a new Phase 2 study in a potentially narrower patient population.
- COVID-19 caused some commercial, manufacturing and clinical-trial disruption. Management characterized the effects as limited and manageable but noted that future impacts remained uncertain.
- The company recorded an $8.6 million loss on early retirement of debt and $120.7 million of stock-based compensation expense in 2021.
- Ionis recognized a $34.8 million R&D expense for the Bicycle technology license and recorded a $7.2 million equity investment in Bicycle.
- Two shareholder-related legal proceedings were disclosed: litigation concerning the Akcea merger and a derivative action alleging excessive director compensation. The filing does not provide a clear estimated loss amount for either matter.
Principal risks and contingencies
- Revenue and cash flow depend substantially on collaboration payments, royalties and the performance of major partners, particularly Biogen, AstraZeneca, Novartis and Roche.
- SPINRAZA faces competition from Zolgensma and Evrysdi, while TEGSEDI and eplontersen face competition from patisiran, tafamidis and other transthyretin therapies.
- TEGSEDI carries a U.S. boxed warning and REMS requirements, and both TEGSEDI and WAYLIVRA require monitoring that may limit market adoption.
- Clinical programs may fail, be delayed, or produce safety or efficacy results that do not support regulatory approval. Tofersen and tominersen already experienced material late-stage setbacks.
- The company relies on contract manufacturers and other third parties for clinical and commercial supply; disruptions, quality failures or cGMP noncompliance could delay development or commercialization.
- Coverage, reimbursement, pricing reform, regulatory changes, intellectual-property challenges and healthcare-cost controls may reduce product revenue.
- Ionis maintains a full valuation allowance against its consolidated U.S. federal and state deferred tax assets. It also reported $55.1 million of gross unrecognized tax benefits.
- Convertible notes, warrants and related call-spread transactions may create future dilution or cash obligations. The filing indicates potential issuance of approximately 17.5 million shares upon conversion of the 0% and 0.125% notes, subject to applicable terms and adjustments.
Investor verification checklist
- Verify the sustainability of revenue excluding the $200 million eplontersen upfront payment and other milestone or license events.
- Review SPINRAZA royalty trends, competitive pressure and Biogen’s reported product sales.
- Assess TEGSEDI and WAYLIVRA net sales and the financial effect of the Sobi and PTC distribution arrangements.
- Track clinical and regulatory milestones for eplontersen, olezarsen, donidalorsen, pelacarsen, ION363 and tofersen.
- Confirm the timing and terms of the $632.5 million 0% notes and the $548.8 million principal amount of 0.125% notes.
- Evaluate operating cash generation relative to research and development spending and future commercialization investments.
- Review the status and potential exposure of the disclosed Akcea merger and director compensation litigation.
- Reconcile the annual financial statements with the revised 2020 and 2019 amounts following adoption of ASU 2020-06 on convertible instruments.